Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide maintenance after autologous stem cell transplantation in multiple myeloma
ACTRN12607000382471Phase 3Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started May 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12607000382471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000382471.